The price-to-earnings ratio for Kiniksa Pharmaceuticals stock stands at 71.1 as of Sep 23, 2026. This is calculated based on the current EPS of $1.07 and the stock price of $76.08 per share. An increase of 19% has been recorded in the P/E ratio compared to the average of 59.9 of the last 4 quarters.
Over the last four years, the average PE ratio of Kiniksa Pharmaceuticals has been 88.45. The current 71.1 PE ratio is 20% below the historical average. In the past four years, KNSA's PE ratio was at its highest in the Jun 2025 quarter at 461.17, with a price of $27.67 and an EPS of $0.06. The Mar 2023 quarter recorded the bottom point at 3.82, with a price of $10.76 and an EPS of $2.82.
Maximum annual increase: 1,446.74% in 2023
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2025 | 51.56 | N/A | $41.25 | $0.8 |
| 2024 | N/A | N/A | $19.78 | -$0.6 |
| 2023 | 87.7 | 1,446.74% | $17.54 | $0.2 |
| 2022 | 5.67 | N/A | $14.98 | $2.64 |
| 2021 | N/A | N/A | $11.77 | -$2.3 |
| 2020 | N/A | N/A | $17.67 | -$2.61 |
| 2019 | N/A | N/A | $11.06 | -$2.99 |
| 2018 | N/A | N/A | $28.09 | -$3.49 |
| 2017 | N/A | N/A | N/A | -$35.85 |
| 2016 | N/A | N/A | N/A | -$91.61 |
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Jun 2026 | 59.77 | 21.66% | $63.95 | $1.07 |
| Mar 2026 | 49.13 | -4.71% | $48.15 | $0.98 |
| Dec 2025 | 51.56 | -34.93% | $41.25 | $0.8 |
| Sep 2025 | 79.24 | -82.82% | $38.83 | $0.49 |
| Jun 2025 | 461.17 | N/A | $27.67 | $0.06 |
| Mar 2025 | N/A | N/A | $22.21 | -$0.24 |
| Dec 2024 | N/A | N/A | $19.78 | -$0.6 |
| Sep 2024 | N/A | N/A | $24.99 | -$0.13 |
| Jun 2024 | N/A | N/A | $18.67 | -$0.15 |
| Mar 2024 | 164.42 | 87.48% | $19.73 | $0.12 |
| Dec 2023 | 87.7 | N/A | $17.54 | $0.2 |
| Sep 2023 | N/A | N/A | $17.37 | -$0.11 |
| Jun 2023 | 4.24 | 10.99% | $14.08 | $3.32 |
| Mar 2023 | 3.82 | -32.63% | $10.76 | $2.82 |
| Dec 2022 | 5.67 | -8.99% | $14.98 | $2.64 |
The Historical Valuation Regime chart shows where the stock's current valuation sits relative to its own historical valuation range over the selected lookback period.
This is a history-relative tool, not a market-relative percentile. It does not compare the stock to other companies. Instead, it compares each historical valuation reading to the stock's own past readings.
The threshold lines are calculated them from the stock's real historical values using percentile interpolation. That is why some colored bands are narrow while others are wide: the band widths reflect how the stock actually traded through time.
| Historical percentile | Regime | Chart meaning |
|---|---|---|
| 0-10 | Historically Low | Deep cheap zone |
| >10-25 | Below Average | Cheap relative to history |
| >25-75 | Average | Within the normal historical range |
| >75-90 | Above Average | Expensive relative to history |
| >90-100 | Historically High | Extreme or stretched valuation |
| Chart element | What it tells you |
|---|---|
| Main line | The actual historical valuation values over time for the selected metric. |
| Dashed horizontal lines | The stock's computed P10, P25, Median, P75, and P90 thresholds for the selected period. |
| Colored bands | The historical valuation zones between those thresholds. |
| Metric boxes | Current ratio, historical median, current percentile, and current regime. |
| Timeline strip | A condensed regime history showing how the stock moved between cheap, fair, and expensive states across each observation. |
Current Percentile is the percentile rank of the latest valid historical observation within the selected lookback range.
Current Regime is assigned directly from the latest observation's percentile bucket using the fixed 10 / 25 / 75 / 90 cutoffs shown above.
This chart is most useful for answering a narrow question: Is this stock trading high, low, or normal relative to its own history? It works best alongside growth, profitability, and forward-looking business analysis, because a stock can deserve a higher or lower regime if its business quality has changed.
Currently, KNSA's PE ratio is lower than the 3 and 5-year averages.
With a P/E of 71.1, KNSA stands above the Healthcare sector and the industry average. Compared to its Healthcare sector average of 23.69, Kiniksa Pharmaceuticals's P/E is 200% higher.
The price to earnings ratio for KNSA stock as of Sep 23, 2026, stands at 71.1.
Over the last 3 years, the average price to earnings ratio for KNSA stock is 136.14.
Over the last 5 years, the average price to earnings ratio for KNSA stock is 88.45.
Over the last four years, the quarterly PE ratio reached a historic high of 461.17 in the Jun 2025 quarter.
The current price to earnings ratio of KNSA is 20% lower than the 4-year historical average.
KNSA's PE ratio of 71.1 is considered high because the company's stock price is trading at a higher multiple of earnings.
To determine the PE ratio, divide the most recent stock price by the TTM earnings per share (EPS). As of today (Sep 23, 2026), Kiniksa Pharmaceuticals's stock price is $76.08. The earnings per share for the trailing twelve months (TTM) ending Jun 2026 is $1.07. Therefore, Kiniksa Pharmaceuticals's P/E ratio for today is 71.1. PE RATIO(71.1) = STOCK PRICE($76.08) / TTM EPS($1.07)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.